Featured Studies

Dr. Regenold and his team at the National Institutes of Health (NIH) are leading a study to explore an investigational new, non-invasive brain stimulation technique to see if it can safely support people experiencing symptoms of depression.

Researchers at the National Institute of Mental Health (NIMH) are studying an investigational drug, HNK, to see if it is effective in treating major depression. If you're 18–70 years old and have major depressive disorder (MDD), you may qualify for this 12- to 14-week inpatient research study.

Researchers are studying the brain's response to language and sound. This study uses a repetitive transcranial magnetic stimulation (rTMS), an investigational form of brain stimulation, to measure how different parts of the brain communicate in teens with autism spectrum disorder (ASD). Findings from this study may aid in the development of possible future treatments.

Researchers are enrolling people with locally advanced or metastatic cancer who are prescribed atezolizumab (alone or with other approved treatments). The study will monitor blood levels to adjust infusion schedules, aiming to see if lower or less frequent doses can be given without reducing effectiveness, over a period of up to 2 years.

Researchers at NCI are developing a new investigational treatment known as TNhYP218 CAR T cells to target and kill tumor cells in people with solid tumors and with those that have high levels of mesothelin (MSLN) including mesothelioma. The study team collects immune cells (T cells); the T cells are genetically modified to target and kill tumor cells to potentially shrink the tumor.

Investigators at the National Cancer Institute (NCI) are enrolling patients with advanced hepatocellular cancers (HCC), in a clinical trial using engineered immune cells, also known as chimeric antigen receptor T-cells or CAR-T cells. In this study, your immune T-cells are collected and modified to target Glypican-3 (GPC3), a protein marker found on the surface of HCC tumors. Researchers hope the altered cells will help identify and fight the cancer cells.

Doctors at the National Cancer Institute (NCI) are looking for volunteers with metastatic cancers, including breast, ovarian, endometrial, gastrointestinal, genitourinary, hepatobiliary, pancreatic, melanoma, non-small cell lung cancer (NSCLC), and multiple myeloma with solid masses. Potential participants will be evaluated with new immunotherapy treatments utilizing cell transfer immunotherapies in a research trial.

Join a National Institutes of Health (NIH) research study seeking mean men who have a genetic risk factor for developing prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at higher risk for prostate cancer.